Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Zeneca Seroquel is "approvable" in U.S., approved in U.K.

  • News

Executive Summary

ZENECA SEROQUEL "APPROVABLE" DESIGNATION AUG. 1 may give Zeneca a chance to close the gap between its antipsychotic agent and Abbott's Serlect, which is also pending approval at FDA. Serlect (sertindole) initially reached the approval stage in October, but Abbott has apparently not yet resolved the outstanding issues raised at that time. The agent was designated approvable for a second time June 16 ("The Pink Sheet" June 30, In Brief).

Table

View full table

Tags:
Latest Headlines

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

First Do No Harm: US MedPAC Wrestles With Complexity Of Low-Cost Drug Pricing

JNJ, BMS’s IRA Loss Is First Time Court Rejects Industry’s First Amendment, Takings Claims

EU Launches Critical Medicines Alliance But Prospect Of Act On Manufacturing Still Uncertain

See All
UsernamePublicRestriction

Register

PS030672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By